Biopharma co. CNS Pharmaceuticals highlights European expansion in Q3 results
CNS Pharmaceuticals has continued expanding its proposed clinical trials into Europe, after it acquired the rights to Berubicin in 2021.
Building "Bridges" Across the Bayou City!
CNS Pharmaceuticals has continued expanding its proposed clinical trials into Europe, after it acquired the rights to Berubicin in 2021.